

Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $332.81
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 22, 26 | Baird | maintain | Outperform | Outperform |
| Oct 20, 26 | Argus Research | maintain | Buy | Buy |
| Oct 16, 26 | UBS | maintain | Buy | Buy |
| Oct 7, 26 | Leerink Partners | maintain | Outperform | Outperform |
| Sep 8, 26 | RBC Capital | maintain | Sector Perform | Sector Perform |
| Aug 11, 26 | Wells Fargo | maintain | Overweight | Overweight |
| Aug 7, 26 | JP Morgan | maintain | Overweight | Overweight |
| Aug 7, 26 | Morgan Stanley | maintain | Overweight | Overweight |
| Aug 6, 26 | UBS | maintain | Buy | Buy |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 1, 26 | Sanchez Robert E | director | A-Award | 275 | — |
| Oct 1, 26 | Krikorian Lazarus | officer: SVP & Chief Accounting Officer | S-Sale | 986 @ $303.18 | $298.9K |
| Oct 1, 26 | Sanchez Robert E | director | 0 | — | |
| Sep 16, 26 | Greenberg Lon R | director | S-Sale | 1,280 @ $321.30 | $411.3K |
| Sep 1, 26 | Krikorian Lazarus | officer: SVP & Chief Accounting Officer | S-Sale | 985 @ $325.97 | $321.1K |
| Aug 24, 26 | Campbell Elizabeth S | officer: Executive Vice President | S-Sale | 11,300 @ $324.12 | $3.66M |
| Jul 31, 26 | Nally Dennis M | director | A-Award | 113 @ $311.34 | $35.18K |
| Jul 31, 26 | Cooper Ellen | director | A-Award | 97 @ $311.34 | $30.20K |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 56.44 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 77.38 | Oscillator | Neutral |
| Williams %R (14) | -37.67 | Oscillator | Neutral |
| MACD (12, 26, 9) | 6.25 (Hist 1.27) | Oscillator | Strong Buy |
| Average Directional Index (14) | 23.92 (+DI 27.4 / -DI 19.3) | Trend | Buy |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
BALA CYNWYD, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Cencora to acquire American Oncology Network in $2.4 billion deal
TTM vs. 5-year historical average (annual ratios)
| Metric | COR | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 24.6x | 24.4x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 18.6x | EPS est. 17.89 | Discount |
| Price / Book | 21.1x | 31.3x | Discount |
| Price / Sales | 0.2x | 0.1x | Elevated |
| EV / EBITDA | 14.1x | 13.0x | In line |
| Return on equity | 106.4% | — | Top tier |
| Gross margin | 3.7% | 3.0% | Above hist. |
| Debt / Equity | 3.84 | 6.76 | Levered |
| Piotroski / Altman Z | 7/9 | Z 4.71 | Safe zone |
Discounted cash flow model
| EMA 20 | 329.32 | MA | Buy |
| SMA 20 | 324.64 | MA | Buy |
| EMA 50 | 321.79 | MA | Strong Buy |
| SMA 50 | 322.08 | MA | Strong Buy |
| SMA 200 | 317.44 | MA | Strong Buy |
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | 4.35 | 4.48 | Beat 3.0% | $84.75B |
| May 6, 2026 | 4.82 | 4.75 | Miss -1.5% | $78.36B |
| Feb 4, 2026 | 4.05 | 4.08 | Beat 0.7% | $85.93B |
| Nov 5, 2025 | 3.79 | 3.84 | Beat 1.3% | $83.73B |
| Aug 6, 2025 | 3.85 | 4.00 | Beat 3.9% | $80.66B |
| May 7, 2025 | 4.11 | 4.42 | Beat 7.5% | $75.45B |
| 8-K | Sep 25, 2026 | 2026-09-25 08:11:17 | View |
| 4 | Sep 17, 2026 | 2026-09-17 15:58:45 | View |
| 4 | Sep 2, 2026 | 2026-09-02 16:00:18 | View |
| 4 | Aug 25, 2026 | 2026-08-25 16:14:41 | View |
| 8-K | Aug 14, 2026 | 2026-08-14 16:06:06 | View |
| 8-K | Aug 12, 2026 | 2026-08-12 12:38:08 | View |
Proxy statement (DEF 14A) disclosures